The Journal of asthma : official journal of the Association for the Care of Asthma · 2025
Real world using dual biological therapy in severe asthma: Insights from four cases.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salameh Laila, Elhassan Mona, Mahboub Bassam
Аннотация
OBJECTIVE: To describe the clinical outcomes of patients with severe uncontrolled asthma who received dual biologic therapy after showing only partial improvement with a single biologic agent.
METHODS: We conducted a descriptive case series of four patients with severe asthma who remained inadequately controlled on biologic monotherapy. A second biologic targeting a different inflammatory pathway was added based on persistent symptoms and biomarker profiles. Clinical outcomes including Asthma Control Test (ACT) scores, asthma exacerbation frequency, oral corticosteroid (OCS) use, and lung function (FEV₁) were evaluated over 12 months of follow-up.
RESULTS: Following dual biologic therapy, all the patients showed significant improvement in Asthma Control Test (ACT) scores, reduction in exacerbations (from a median of 9 to 0.5/year), and reduced oral corticosteroid (OCS) usage (median 9 to 0.5/year). FEV1 remained stable or improved. No significant adverse effects were noted during 12 months of follow-up.
CONCLUSION: This series highlights that dual biologic therapy is effective and safe in a carefully selected difficult subgroup of severe uncontrolled asthma.
METHODS: We conducted a descriptive case series of four patients with severe asthma who remained inadequately controlled on biologic monotherapy. A second biologic targeting a different inflammatory pathway was added based on persistent symptoms and biomarker profiles. Clinical outcomes including Asthma Control Test (ACT) scores, asthma exacerbation frequency, oral corticosteroid (OCS) use, and lung function (FEV₁) were evaluated over 12 months of follow-up.
RESULTS: Following dual biologic therapy, all the patients showed significant improvement in Asthma Control Test (ACT) scores, reduction in exacerbations (from a median of 9 to 0.5/year), and reduced oral corticosteroid (OCS) usage (median 9 to 0.5/year). FEV1 remained stable or improved. No significant adverse effects were noted during 12 months of follow-up.
CONCLUSION: This series highlights that dual biologic therapy is effective and safe in a carefully selected difficult subgroup of severe uncontrolled asthma.